# (19) World Intellectual Property Organization International Bureau



## 

# (43) International Publication Date 15 March 2001 (15.03.2001)

#### PCT

# (10) International Publication Number WO 01/17543 A3

- (51) International Patent Classification<sup>7</sup>: A61K 38/17, 39/395, A61P 19/00, 35/02, 35/04 // (A61K 38/17, 38:09) (A61K 39/395, 38:17)
- (21) International Application Number: PCT/US00/22806
- (22) International Filing Date: 18 August 2000 (18.08.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: 09/389,545 3 September 1999 (03.09.1999)
- (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).
- (72) Inventor: DUNSTAN, Colin, R.; 887 Tupelo Wood Court, Newbury Park, CA 91320 (US).
- (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., One Amgen Center Drive, M/S 27-4-A, Thousand Oaks, CA 91320-1799 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report: 26 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

543

(54) Title: COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF CANCER AND BONE LOSS ASSOCIATED WITH CANCER

(57) Abstract: The present invention relates to compositions and methods for the prevention and/or treatment of bone loss associated with cancer. More particularly, the invention relates to OPG compositions and methods for the prevention and/or treatment of bone loss comprising said compositions. The invention also relates to the use of OPG compositions for the treatment of multiple myeloma.

Inte Jonal Application No PCT/US 00/22806

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61K A61P35/04 A61P35/02 A61K39/395 A61P19/00 //(A61K38/17.38:09),(A61K39/395,38:17) According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) A61K C07K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ' 1-15,21, EP 0 784 093 A (AMGEN INC) 16 July 1997 (1997-07-16) 22 16-20 abstract Y page 2, line 20 -page 3, line 6 page 7, line 24 - line 29 page 8, line 41 -page 9, line 10 page 12, line 17 - line 47 page 41, line 5 -page 42, line 5 page 45, line 30 -page 48, line 7 page 60, line 30 - line 41 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. ° Special categories of cited documents: "T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance Invention "E" earlier document but published on or after the international 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-\*O\* document reterring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means \*P\* document published prior to the international filing date but tater than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 22 February 2001 28/02/2001 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl. Noë, V Fax: (+31-70) 340-3016

2

Inti Jonal Application No PCT/US 00/22806

	TO SELECT TO BE SELECTED.	PCT/US 00/22806	
C.(Continu Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	SIMONET W ET AL: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density" CELL,US,CELL PRESS, CAMBRIDGE, NA, no. 89, 18 April 1997 (1997-04-18), pages 309-319, XP002077048 ISSN: 0092-8674 abstract figure 5C page 314 -page 315, column 1, paragraph 1 page 315, column 2, last paragraph -page 316, column 1, paragraph 1	1-3, 5-10,13, 21	
Ρ,Χ	page 317, column 1, paragraph 2  MORONY S ET AL: "A CHIMERIC FORM OF OSTEOPROTEGERIN INHIBITS HYPERCALCEMIA AND BONE RESORPTION INDUCED BY IL-1BETA, TNF-ALPHA, PTH, PTHRP, AND 1,25(OH)2D3" JOURNAL OF BONE AND MINERAL RESEARCH,NEW YORK, NY,US, vol. 14, no. 9, September 1999 (1999-09), pages 1478-1485, XP000971493 ISSN: 0884-0431 abstract page 1478, column 2, paragraph 1 page 1479, column 1, paragraph 1 page 1483, column 2, last paragraph	1-3, 5-10,13, 14,21	
Y	US 5 843 901 A (ROESKE ROGER W)  1 December 1998 (1998-12-01)  cited in the application  column 1, line 64 -column 2, line 3  column 2, line 36 - line 40  column 10, line 56 -column 11, line 20  column 13, line 55 - line 60  column 17, line 15 - line 18  column 17, line 38 - line 42	18-20	
Y	PERIGAUD C ET AL: "NUCLEOSIDE ANALOGUES AS CHEMOTHERAPEUTIC AGENTS: A REVIEW" NUCLEOSIDES & NUCLEOTIDES, US, DEKKER, NEW YORK, NY,, vol. 11, no. 2/04, 1992, pages 903-945, XP000607988 ISSN: 0732-8311 page 907, last paragraph -page 909, paragraph 1  -/	16	

Inte .onal Application No PCT/US 00/22806

C (Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	101703 00722000
Category Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
Y	X YANG ET AL: "Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 59, no. 5, 15 March 1999 (1999–03–15), pages 1236–1243, XP002156618 ISSN: 0008–5472 the whole document	17

Information on patent family members

Int. atlanal Application No
PCT/US 00/22806

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
EP 0784093 A		16-07-1997	AU	710587 B	23-09-1999	
EL 0/04032	^	10 0, 133,	AU	1468697 A	17-07-1997	
			BG	101813 A	30-09-1998	
			ČĀ	2210467 A	03-07-1997	
			CN	1182452 A	20-05-1998	
			CZ	9702538 A	17-03-1999	
			DE	19654610 A	26-06-1997	
			EP	0870023 A	14-10-1998	
			FR	2742767 A	27-06-1997	
			GB	2312899 A,B	12-11-1997	
			HU	9801122 A	28-08-1998	
			JP	11503616 T	30-03-1999	
			NO	973699 A	21-10-1997	
			NZ	326579 A	28-01-1999	
			PL	321938 A	05-01-1998	
			SK	110797 A	12-07-1999	
			TR	970550 A	21-07-1997	
			WO	9723614 A	03-07-1997	
			US	6015938 A	18-01-2000	
US 5843901	Α	01-12-1998	AU	715399 B	03-02-2000	
02 2042301	A	01 12 1330	AU	6168096 A	30-12-1996	
			CA	2219460 A	19-12-1996	
			EP	0794961 A	17-09-1997	
			JP	11507374 T	29-06-1999	
			WO	9640757 A	19-12-1996	